Multiple Myeloma

Among patients with newly diagnosed high-risk multiple myeloma, treatment with BCMA/CD19 dual-targeting FasTCAR-T Cells resulted in an overall response rate of 100%, with all treated patients evaluable for minimal residual disease showing minimal residual disease negativity to 12 months.

The CAR-T cell therapy ciltacabtagene autoleucel has expanded options for adult patients with relapsed/refractory multiple myeloma after 4 or more lines of prior therapy in the United States, and has continued to display promising efficacy in patients with multiple myeloma following early relapse.

Single-agent belantamab mafodotin continued to produce rapid, deep, and durable responses in patients with relapsed/refractory multiple myeloma.

The combination of belantamab mafodotin, pomalidomide, and dexamethasone elicited encouraging responses and survival benefits in patients with triple class–exposed or refractory multiple myeloma.

In this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.

Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

Jesus G. Berdeja, MD, discusses the investigation of BMS-986393 in patients with relapsed/refractory multiple myeloma.

Daratumumab in addition to bortezomib, lenalidomide, and dexamethasone induction/consolidation therapy, as well as with lenalidomide maintenance, showcased a promising health-related quality of life benefit for patients with transplant eligible, newly diagnosed multiple myeloma.

Mezigdomide showed notable clinical activity and a manageable safety profile when combined with dexamethasone in patients with triple-class relapsed or refractory multiple myeloma.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

The GPRC5D- and CD3-directed bispecific antibody forimtamig led to high response rates in patients with relapsed or refractory multiple myeloma regardless of subcutaneous or intravenous administration, according to updated findings from a phase 1 dose-escalation study.

Administration of teclistamab in combination with daratumumab and lenalidomide demonstrated promising overall response rates and tolerability in patients with relapsed/refractory multiple myeloma who had prior lenalidomide exposure, according to initial data from the phase 1b MajesTEC-2 trial.

Sandra P. Susanibar-Adaniya, MD, discusses 2 key trials in multiple myeloma that improved the treatment landscape for transplant-eligible and ineligible patients.

S. Vincent Rajkumar, MD, previews his top 5 abstracts in multiple myeloma ahead of the 2022 ASH Annual Meeting.

Oncopeptides AB announced December 7, 2022, that the FDA has asked the company to withdraw melphalan flufenamide from the US market.

Building on research his father conducted decades earlier, Robert Orlowski, MD, PhD, redefined myeloma treatment.

Sandra P. Susanibar-Adaniya, MD, discusses the current standard of care for patients with newly diagnosed multiple myeloma.

Murali Janakiram, MD, MS, discusses future targets and research strategies for CAR T-cell therapy in multiple myeloma.

GlaxoSmithKline plc has initiated the process to withdraw the United States marketing authorization for belantamab mafodotin-blmf for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 4 prior therapies.

Shambavi Richard, MD, discussed key studies that continue to shape the SOC in both the transplant-eligible and -ineligible populations, the role of transplant in the space, and unmet needs that remain for older and frail patients.

The increasing integration of CAR T-cell therapies into the treatment paradigm for adult patients with relapsed or refractory multiple myeloma addresses several unmet needs and improves outcomes for this historically limited patient population.

Belantamab mafodotin-blmf did not generate a progression-free survival benefit vs the combination of pomalidomide plus low-dose dexamethasone, failing to meet the primary end point of the phase 3 DREAMM-3 trial.

Joseph Mikhael, MD, and Craig Cole, MD, close the program by sharing examples of times culturally competent care was paramount to the treatment of their patients.

The FDA has granted a breakthrough therapy designation to elranatamab for the treatment of patients with relapsed/refractory multiple myeloma.

Peter Voorhees, MD, discusses developments in the efficacy and application of proteasome inhibitors for patients with newly diagnosed multiple myeloma.

ABBV-383 was effective and well tolerated at all administered doses in patients with relapsed/refractory multiple myeloma, according to safety and efficacy results from an ongoing first-in-human, phase 1 dose-escalation/-expansion study.

Sandra P. Susanibar-Adaniya, MD, discusses how advancements in triplet therapy have shifted the treatment paradigm for patients with newly diagnosed, transplant-ineligible multiple myeloma.

Ciltacabtagene autoleucel produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma treated at 8 sites in China.

Expert panelists share their closing thoughts on the path to improve health equity in multiple myeloma management for racial and ethnic minority groups.

Craig Cole, MD, shares advice for community physicians on providing culturally competent care to patients with multiple myeloma that embraces their beliefs, spiritualities, and ethnicities.